ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial

Lu, Zhihao; Wang, Junye; Shu, Yongqian; Liu, Lianke; Kong, Li; Yang, Lei; Wang, Buhai; Sun, Guogui; Ji, Yinghua; Cao, Guochun; Liu, Hu; Cui, Tongjian; Li, Na; Qiu, Wensheng; Li, Gaofeng; Hou, Xinfang; Luo, Hui; Xue, Liying; Zhang, Yanqiao; Yue, Wenbin; Liu, Zheng; Wang, Xiuwen; Gao, Shegan; Pan, Yueyin; Galais, Marie-Pierre; Zaanan, Aziz; Ma, Zhuo; Li, Haoyu; Wang, Yan; Shen, Lin*北京大学; 青岛大学; 山东大学; 山东省医学科学院; 哈尔滨医科大学; 1
BRITISH MEDICAL JOURNAL2022-4-19DOI: 10.1136/bmj-2021-068714
127被引14阅读
引用收藏
分享

摘要

OBJECTIVE @@@ To evaluate sintilimab versus placebo in combination with chemotherapy (cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil) as first line treatment of unresectable locally advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. @@@ DESIGN @@@ Multicentre, randomised, double blind, phase 3 trial. @@@ SETTING @@@ 66 sites in China and 13 sites outside of China between 14 December 2018 and 9 April 2021. @@@ PARTICIPANTS @@@ 659 adults (aged >= 18 years) with advanced or metastatic oesophageal squamous cell carcinoma who had not received systemic treatment. @@@ INTERVENTION @@@ Participants were randomised 1:1 to receive sintilimab or placebo (3 mg/kg in patients weighing <60 kg or 200 mg in patients weighing >= 60 kg) in combination with cisplatin 75 mg/m(2) plus paclitaxel 175 mg/m(2) every three weeks. The trial was amended to allow investigators to choose the chemotherapy regimen: cisplatin plus paclitaxel or cisplatin plus 5-fluorouracil (800 mg/m(2) continuous infusion on days 1-5). @@@ MAIN OUTCOME MEASURES @@@ Overall survival in all patients and in patients with combined positive scores of >= 10 for expression of programmed cell death ligand 1. @@@ RESULTES @@@ 659 patients were randomly assigned to sintilimab (n=327) or placebo (n=332) with chemotherapy. 616 of 659 patients (93%) received sintilimab or placebo in combination with cisplatin plus paclitaxel and 43 of 659 patients (7%) received sintilimab or placebo in combination with cisplatin plus 5-fluorouracil. At the interim analysis, sintilimab with chemotherapy showed better overall survival compared with placebo and chemotherapy in all patients (median 16.7 v 12.5 months, hazard ratio 0.63, 95% confidence interval 0.51 to 0.78, P<0.001) and in patients with combined positive scores of (17.2 v 13.6 months, 0.64, 0.48 to 0.85, P=0.002). Sintilimab and chemotherapy significantly improved progression free survival compared with placebo and chemotherapy in all patients (7.2 v 5.7 months, 0.56, 0.46 to 0.68, P<0.001) and in patients with combined positive scores of >= 10 (8.3 v 6.4 months, 0.58, 0.45 to 0.75, P<0.001). Adverse events related to treatment occurred in 321 of 327 patients (98%) in the sintilimab-chemotherapy group versus 326 of 332 (98%) patients in the placebo-chemotherapy group. Rates of adverse events related to treatment, grade were 60% (196/327) and 55% (181/332) in the sintilimab-chemotherapy and placebo-chemotherapy groups, respectively. @@@ CONCLUSION @@@ Compared with placebo, sintilimab in combination with cisplatin plus paclitaxel showed significant benefits in overall survival and progression free survival as first line treatment in patients with advanced or metastatic oesophageal squamous cell carcinoma. Similar benefits of sintilimab with cisplatin plus 5-fluorouracil seem promising.

学科与关键词

关键词
OPEN-LABEL1ST-LINE TREATMENTPLUSCAMRELIZUMABPLATINUMNSCLC
相关
加载中…
  • Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
    Xu, Jianming*; Li, Yi; Fan, Qingxia; Shu, Yongqian; Yang, Lei; Cui, Tongjian; Gu, Kangsheng; Tao, Min; Wang, Xiuwen; Cui, Chengxu; Xu, Nong; Xiao, Juxiang; Gao, Quanli; Liu, Yunpeng; Zhang, Tao; Bai, Yuxian; Li, Wei; Zhang, Yiping; Dai, Guanghai; Ma, Dong; Zhang, Jingdong; Bai, Chunmei; Huang, Yunchao; Liao, Wangjun; Wu, Lin; Chen, Xi; Yang, Yan; Wang, Junye; Ji, Shoujian; Zhou, Hui; Wang, Yan; Ma, Zhuo; Wang, Yanqi; Peng, Bo; Sun, Jiya; Mancao, ChristophNature Communications, 2022, 13(1): 857.被引 48
  • Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial
    Xu, Jianming*; Jiang, Haiping; Pan, Yueyin; Gu, Kangsheng; Cang, Shundong; Han, Lei; Shu, Yongqian; Li, Jiayi; Zhao, Junhui; Pan, Hongming; Luo, Suxia; Qin, Yanru; Guo, Qunyi; Bai, Yuxian; Ling, Yang; Yang, Jianwei; Yan, Zhilong; Yang, Lei; Tang, Yong; He, Yifu; Zhang, Liangming; Liang, Xinjun; Niu, Zuoxing; Zhang, Jingdong; Mao, Yong; Guo, Yingmei; Peng, Bo; Li, Ziran; Liu, Ying; Wang, Yan; Zhou, HuiJAMA, 2023, 330(21): 2064-2074.
  • First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial
    Song, Yan; Zhang, Bo; Xin, Dao; Kou, Xiaoge; Tan, Zhenbo; Zhang, Shu; Sun, Meili; Zhou, Jin; Fan, Min; Zhang, Ming; Song, Yongxiang; Li, Suyi; Yuan, Yuan; Zhuang, Wu; Zhang, Jingdong; Zhang, Li; Jiang, Hao; Gu, Kangsheng; Ye, Huangyang; Ke, Ying; Li, Jing; Wang, Qingyu; Zhu, Jun; Huang, Jing*Nature Medicine, 2023, 29(2).被引 25
查看全部 →

发表信息

论文状态
公开发表
期刊
BRITISH MEDICAL JOURNAL
发表日期
2022-04-19
卷期
第 377 卷
页码
e068714
DOI
10.1136/bmj-2021-068714
成果收录
SCIE
资助标注
Innovent Biologics (Suzhou, Jiangsu, China); Eli Lilly

作者

  • L

    Lu, Zhihao (第一作者)

    peking univ

  • W

    Wang, Junye

    jining med coll

查看全部 30 位作者收起作者
  • S

    Shu, Yongqian

    1 · nanjing med univ

  • L

    Liu, Lianke

    1 · nanjing med univ

  • K

    Kong, Li

    shandong acad med sci

  • Y

    Yang, Lei

  • W

    Wang, Buhai

    yangzhou univ

  • S

    Sun, Guogui

  • J

    Ji, Yinghua

    1 · xinxiang med univ

  • C

    Cao, Guochun

    nanjing med univ

  • L

    Liu, Hu

    univ sci & technol china

  • C

    Cui, Tongjian

    fujian prov hosp

  • L

    Li, Na

  • Q

    Qiu, Wensheng

    qingdao univ

  • L

    Li, Gaofeng

    2

  • H

    Hou, Xinfang

  • L

    Luo, Hui

    2 · jiangxi canc hosp

  • X

    Xue, Liying

  • Z

    Zhang, Yanqiao

    2 · harbin med univ

  • Y

    Yue, Wenbin

  • L

    Liu, Zheng

  • W

    Wang, Xiuwen

    shandong univ

  • G

    Gao, Shegan

    1 · henan univ

  • P

    Pan, Yueyin

    anhui prov hosp

  • G

    Galais, Marie-Pierre

  • Z

    Zaanan, Aziz

  • M

    Ma, Zhuo

  • L

    Li, Haoyu

  • W

    Wang, Yan

  • S

    Shen, Lin (通讯)

    peking univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417